X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Syncona gains access to FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, currently in Phase 1/2 clinical trial in people with Gaucher disease type 1.
Lead Product(s): FLT201
Therapeutic Area: Genetic Disease Product Name: FLT201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syncona
Deal Size: $28.3 million Upfront Cash: $28.3 million
Deal Type: Acquisition February 20, 2024
Details:
Through the acquisition, Syncona gains access to FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, currently in Phase 1/2 clinical trial in people with Gaucher disease type 1.
Lead Product(s): FLT201
Therapeutic Area: Genetic Disease Product Name: FLT201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syncona
Deal Size: $28.3 million Upfront Cash: $28.3 million
Deal Type: Acquisition November 22, 2023
Details:
FLT201 is an adeno-associated virus (AAV) gene therapy candidate which is currently being investigated in the GALILEO-1 Phase 1/2 clinical trial in adults with Gaucher disease type 1.
Lead Product(s): FLT201
Therapeutic Area: Genetic Disease Product Name: FLT201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
FLT201 is an adeno-associated virus (AAV) gene therapy candidate which is currently being investigated in the GALILEO-1 Phase 1/2 clinical trial in adults with Gaucher disease type 1.
Lead Product(s): FLT201
Therapeutic Area: Genetic Disease Product Name: FLT201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
FLT201 is an adeno-associated virus (AAV) gene therapy enhacer of GCase level that is currently being investigated in the GALILEO-1 Phase 1/2 clinical trial in adults with Gaucher disease type 1.
Lead Product(s): FLT201
Therapeutic Area: Genetic Disease Product Name: FLT201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Under the terms of the agreement, Freeline gains rights to develop and commercialise AAV-based gene therapies for certain cardiac conditions using key targets identified by Forcefield.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Forcefield Therapeutics
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Agreement April 04, 2023
Details:
FLT190 is designed to generate durable increases in α-Gal A levels and reduce substrate accumulation, with the aim of providing a one-time treatment that can stop disease progression and improve outcomes. It s currently being investigated for fabry disease.
Lead Product(s): FLT190
Therapeutic Area: Genetic Disease Product Name: FLT190
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
FLT190 is a gene therapy candidate designed to generate durable plasma α-Gal A levels above the normal range to enable sufficient enzyme activity in relevant tissues with a one-time treatment.
Lead Product(s): FLT190
Therapeutic Area: Genetic Disease Product Name: FLT190
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
FLT180a (verbrinacogene setparvovec), uses a potent AAVS3 capsid rationally designed for effective targeting and transduction of liver cells and containing an expression cassette encoding a gain of function Padua variant of human factor IX (FIX).
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University College London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
B-LIEVE is a Phase 1/2 dose confirmation trial of FLT180a (verbrinacogene setparvovec) using a short course of prophylactic immune management with the goal of normalizing FIX levels in patients with severe and moderately severe hemophilia B.
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
